← Back to Clinical Trials
Recruiting NCT04704115

The Therapy of Large Endometrioma

Trial Parameters

Condition Endometrioma
Sponsor University Hospital, Lille
Study Type OBSERVATIONAL
Phase N/A
Enrollment 62
Sex FEMALE
Min Age 18 Years
Max Age 40 Years
Start Date 2021-01-21
Completion 2026-12

Brief Summary

Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility and ovarian reserve. Currently, there's no recommendation about large endometrioma's treatment and there's no information on the best treatment to limit recurrences, preserve fertility and ovarian reserve. In Lille university hospital, simple laparoscopic drainage associated with hormonal therapy is practiced to reduce the risk of cystectomy. This protocol will be evaluated with an observational and prospective study, including women of childbearing age having endometrioma measuring 6 cm or above. The aim of this study is to assess if cyst drainage associated with GnRH agonist, could decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact on anti-mullerian hormone

Eligibility Criteria

Inclusion Criteria: * Endometrioma size ≥ 6cm determined by MRI or ultrasonography * Women with isolated endometrioma or other extraovarian endometriosis: peritoneal, infiltrating endometriotic lesions and adenomyosis. * Cyst single or bilateral Exclusion Criteria: * Cyst with radiographic or macroscopic in laparoscopy atypia * Pregnancy * Patient with contraindication to GnRH agonist (Enantone® 3,75 mg et Decapeptyl® 3 mg) * Patient with contraindication to laparoscopy * Patient with contraindication to general anesthesia * Subject refusing to participate in the study

Related Trials